Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
Authors:
- Yifei WangYWYifei Wang
- Zhongting ZhangZZZhongting Zhang
- Caterina LongoCLCaterina Longo
- Wendong ZhangWZWendong Zhang
- Qi WangQWQi Wang
- Amer NajjarANAmer Najjar
- Xiangjun TianXTXiangjun Tian
- Rossana N. Lazcano SeguraRSRossana N. Lazcano Segura
- Michael E. RothMRMichael E. Roth
- Jonathan GillJGJonathan Gill
- Douglas J. HarrisonDHDouglas J. Harrison
- Zhaohui XuZXZhaohui Xu
Open Access
- 10 January 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 881-896
Abstract
Due to the paucity of validated cell-surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody–drug conjugate (ADC) therapy observed in patients with several solid and hematologic malignancies. Our comprehensive surfaceome profiling approach previously identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC. We tested a CADM1-targeting ADC with a tesirine payload (SG3249) in vitro in osteosarcoma, rhabdomyosarcoma, and neuroblastoma patient-derived xenograft (PDX) cell lines. In vivo, we tested six CADM1-expressing osteosarcoma PDX models. The CADM1 ADC demonstrated significant antitumor activity in vitro across the osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines. Additionally, it effectively reduced tumor volume and extended event-free survival in all six osteosarcoma PDX models tested. Notably, the CADM1 ADC achieved a major complete response in one model (OS2), complete responses in two models (OS1 and OS33), and partial responses in three models (OS9, OS17, and OS31). Based on these results, clinical development of CADM1-targeted therapies for osteosarcoma and other CADM1-expressing pediatric solid tumors may be warranted.Keywords
All Related Versions
Funding Information
- Swim Across America
- Cancer Prevention and Research Institute of Texas (RP240440)
- Foster Foundation
- National Cancer Institute (5U01CA199221-06)
- National Cancer Institute (P50 CA302482)
- Osteosarcoma Institute
- QuadW foundation
- H. Grant Taylor, M.D., W.W. Sutow, M.D. and Margaret P. Sullivan, M.D. Distinguished Chair in Pediatrics
- Barbara Epstein Foundation
This publication has 37 references indexed in Scilit:
- Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesionCellular and Molecular Life Sciences, 2012
- The development of pyrrolobenzodiazepines as antitumour agentsExpert Opinion on Investigational Drugs, 2011
- Impairment of Methotrexate Transport Is Common in Osteosarcoma Tumor SamplesSarcoma, 2010
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical ModelJournal of Clinical Oncology, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Platelet‐derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcomaCancer, 2008
- The pediatric preclinical testing program: Description of models and early testing resultsPediatric Blood & Cancer, 2006
- EXPRESSION OF THE HER-2/NEU PROTOONCOGENE IN NORMAL HUMAN ADULT AND FETAL TISSUES1990